Akebia Therapeutics, Inc. (AKBA) NASDAQ

1.42

+0.01(+0.71%)

Updated at April 22 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
John Butler	CEO, President & Director	1.93M	1964
Erik John Ostrowski	Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer	412,812	1972
Nicholas Grund	Senior VP & Chief Commercial Officer	684,224	1970
Steven Keith Burke	Senior VP and Chief Research & Development Officer	1.03M	1961
Mercedes Carrasco	Senior Director of Investor & Corporate Communications	0	N/A
Richard C. Malabre	Chief Accounting Officer	0	1961
Carolyn Rucci	Senior VP of Legal, General Counsel & Secretary	0	N/A
Kimberly Garko	Senior VP & Chief Technical Officer	0	N/A
Meredith Bowman	Senior VP & Chief People Officer	0	N/A
Tracey Vetterick	Vice President of Portfolio Strategy & Corporate Administration	0	N/A

Name

Title

Pay

Year Born

John Butler

CEO, President & Director

1.93M

1964

Erik John Ostrowski

Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer

412,812

1972

Nicholas Grund

Senior VP & Chief Commercial Officer

684,224

1970

Steven Keith Burke

Senior VP and Chief Research & Development Officer

1.03M

1961

Mercedes Carrasco

Senior Director of Investor & Corporate Communications

N/A

Richard C. Malabre

Chief Accounting Officer

1961

Carolyn Rucci

Senior VP of Legal, General Counsel & Secretary

N/A

Kimberly Garko

Senior VP & Chief Technical Officer

N/A

Meredith Bowman

Senior VP & Chief People Officer

N/A

Tracey Vetterick

Vice President of Portfolio Strategy & Corporate Administration

N/A

Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.